Cabozantinib is an oral multitarget TKI approved for the treatment of advanced hepatocellular carcinoma (HCC) in patients who have previously been treated with sorafenib, for advanced or metastatic differentiated thyroid carcinoma in patients refractory or not eligible to radioactive iodine who have progressed on prior systemic therapy, and for advanced intermediate or poor risk renal cell carcinoma (RCC)—as first-line treatment or following prior VEGF-targeted therapy [36–39]. Here, VEGFA is linked to renal cell carcinoma.